Rabbit and human hepatitis E virus strains belong to a single serotype

The classification of emerging viral strains often remains ambiguous regarding their immunological relationship to established pathogens. Hepatitis E virus is a recognized zoonotic agent with four primary genotypes sharing a single serotype. Recent discovery of a rabbit-specific strain raised questions about its potential classification within this existing framework. No prior work had resolved whether this novel variant shares the same immunological profile as human strains. This uncertainty drove the need for rigorous comparative serological assessment. Prior research has shown that capsid proteins serve as primary targets for host immune responses. Understanding these interactions is vital for assessing cross-species transmission risks. This gap motivated the current investigation into the serotypic alignment of these distinct viral lineages.

The aim of this study was to determine the serotypic relationship between rabbit and human hepatitis E virus strains. Researchers sought to resolve whether the recently identified rabbit variant falls within the established serotype of human-infecting genotypes. This investigation was motivated by the need to understand the potential for cross-species transmission and the implications for public health. The team addressed the ambiguity surrounding the immunological classification of this zoonotic pathogen. By comparing the neutralization profiles of these viruses, they intended to clarify their taxonomic status. The study also explored whether prior infection with one strain confers protection against the other in an animal model. This work addresses a critical gap in current knowledge regarding the breadth of hepatitis E virus serotypes. The researchers designed these experiments to provide a definitive answer to the question of serotypic alignment.

The review approach involved a comparative analysis of immunological responses to diverse viral strains. Investigators generated immune sera using recombinant capsid proteins derived from four established human genotypes and the rabbit variant. These sera were tested against human genotypes one and four, alongside the rabbit strain, using a specialized neutralization protocol. The team established rabbit models using the JS204-2 and NJ703 strains to evaluate in vivo protection. They monitored fecal shedding and viremia to track infection progress in these animal subjects. Researchers challenged recovered rabbits with heterologous viral strains to assess cross-protection. They recorded anti-HEV IgG levels to determine the kinetics of the host immune response. This methodology ensured a comprehensive evaluation of both humoral and systemic immunity across species.

The researchers observed that immune sera from all five capsid proteins successfully neutralized or cross-neutralized the three tested viral strains. This finding confirms the existence of common neutralization epitopes shared between human and rabbit variants. In the animal models, rabbits recovered from JS204-2 infection showed no detectable viremia when challenged with the NJ703 strain. Similarly, those previously infected with NJ703 remained free of viremia upon exposure to the rabbit strain. The team documented shorter durations of fecal virus shedding in these challenged subjects compared to naive controls. They also noted an obvious early stage decline in anti-HEV IgG values following the secondary viral challenge. These results provide strong evidence that the rabbit strain shares a serotype with human-infecting viruses. The data consistently point toward a unified immunological classification for these zoonotic agents.

The authors propose that rabbit and human hepatitis E virus strains are members of the same serotype. This synthesis suggests that existing human vaccines might offer protection against rabbit-derived viral variants. The evidence indicates that cross-neutralization occurs between these distinct strains due to shared epitopes on the capsid protein. These findings imply that zoonotic transmission risks could be managed through unified immunological strategies. The researchers conclude that the immunological barrier between these hosts is lower than previously suspected. Their data support the classification of rabbit strains within the broader human-infecting viral group. This study provides a foundation for future cross-species vaccination policies. The authors emphasize that these results clarify the taxonomic status of the rabbit-specific pathogen.